<?xml version="1.0" encoding="UTF-8"?>
<boxed-text id="BX1" position="float" orientation="portrait">
 <caption>
  <title>Strengths and limitations of this study</title>
 </caption>
 <list list-type="bullet">
  <list-item>
   <p>IP2-ATLANTA addresses an important research gap in the role of local and metastasis-directed therapy in men with newly diagnosed metastatic prostate cancer.</p>
  </list-item>
  <list-item>
   <p>This is the first phase II trial to include cytoreductive minimally invasive ablative therapy alongside cytoreductive radical prostatectomy and prostate radiotherapy.</p>
  </list-item>
  <list-item>
   <p>The IP2-ATLANTA study builds on the clinical benefits derived from metastasis-directed therapy (stereotactic ablative body radiotherapy and/or surgery) in a previously untreated cohort of men with advanced disease.</p>
  </list-item>
  <list-item>
   <p>Due to invasive interventions, blinding is not possible in the IP2-ATLANTA study.</p>
  </list-item>
 </list>
</boxed-text>
